Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T17:42:23.620Z Has data issue: false hasContentIssue false

Drug treatment of personality disorder

Published online by Cambridge University Press:  02 January 2018

Peter Tyrer*
Affiliation:
Imperial College School of Medicine, Paterson Centre, London W2 1PD
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

For many involved in the management of people with personality disorders the title of this article may appear to be a contradiction; drugs may alter mental state but intrinsically seem unlikely to alter personality. Nevertheless, drugs are available for treating personality disorders (even though none of them are licensed for these conditions). So it is hardly surprising that there is now a considerable body of literature on the subject which has recently been extensively reviewed (Stein, 1992) but which has attracted more attention since personality disorders have achieved greater prominence in all parts of psychiatric practice.

Type
Drug Information Quarterly
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

Cornelius, J. R., Soloff, P. H., Perel, J. M., et al (1993) Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry, 150, 18431848.Google Scholar
Cowdry, R. W. & Gardner, D. L. (1988) Pharmacotherapy of borderline personality disorder: alprazolam. carbamazepine, trifluoperazine and tranylcypromine. Archives of General Psychiatry, 45, 111119.Google Scholar
De Girolamo, G. & Reich, J. H. (1993) Personality Disorders. Geneva: World Health Organization.Google Scholar
Deltito, J. A. & Stam, M. (1989) Psychopharmacological treatment of avoidant personality disorder. Comprehensive Psychiatry, 30, 498504.Google Scholar
George, A. & Soloff, P. H. (1986) Schizotypal symptoms in patients with borderline personality disorders. American Journal of Psychiatry, 143, 212215.Google Scholar
Goldberg, S. C., Shulz, S. C., Shulz, P. M., et al (1986) Borderline and schizotypal personality disorders treated with low dose thiothixene versus placebo. Archives of General Psychiatry, 43, 680686.CrossRefGoogle Scholar
Herbert, J. D., Hope, D. A. & Bellack, A. S. (1992) Validity of the distinction between generalized social phobia and avoidant personality disorder. Journal of Abnormal Psychology, 101, 332339.Google Scholar
Klar, H. & Siever, L. J. (1984) The psychopharmacologic treatment of personality disorders. Psychiatric Clinics of North America, 7, 791801.Google Scholar
Links, P. S., Steiner, M., Boiago, I., et al (1990) Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders, 4, 173181.CrossRefGoogle Scholar
Merry, J., Reynolds, C. M., Bailey, J., et al (1976) Prophylactic treatment of alcoholism by lithium carbonate. Lancet, ii, 481482.Google Scholar
Murphy, S. M. & Tyrer, P. (1991) A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. British Journal of Psychiatry, 158, 511516.Google Scholar
Reich, J. & Thompson, W. D. (1987) DSM–III personality disorder clusters in three generations. British Journal of Psychiatry, 150, 471475.Google Scholar
Salzman, C., Wolfson, A. N., Schatzberg, A., et al (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 2329.Google Scholar
Shawcross, C. R. & Tyrer, P. (1985) Influence of personality on response to monoamine oxidase inhibitors and tricyclic antidepressants. Journal of Psychiatric Research, 19, 557562.Google Scholar
Shea, M. T., Pilkonis, P. A., Beckham, E., et al (1990) Personality disorders and treatment outcome in the NIMH treatment of depression collaborative research program. American Journal of Psychiatry, 147, 711718.Google Scholar
Sheard, M. H., Marini, J. L., Bridges, C. I., et al (1976) The effect of lithium on impulsive aggressive behavior in man. American Journal of Psychiatry, 133, 14091413.Google Scholar
Soloff, P. H. (1994) Is there any drug treatment of choice for the borderline patient? Acta Psychiatrica Scandinavica, 89 (suppl. 379), 5055.Google Scholar
Soloff, P. H., George, A., Nathan, R. S., et al (1986) Progress in pharmacotherapy of personality disorders: a double blind study of amitriptyline, haloperidol and placebo. Archives of General Psychiatry, 43, 691697.Google Scholar
Stein, G. S. (1992) Drug treatment of the personality disorders. British Journal of Psychiatry, 161, 167184.Google Scholar
Tyrer, P. (1985) Neurosis divisible? Lancet, i, 685688.Google Scholar
Tyrer, P. & Johnson, T. (1996) Establishing the severity of personality disorder. American Journal of Psychiatry, 153, 15931597.Google ScholarPubMed
Tyrer, P., Owen, R. & Dawlings, S. (1983) Gradual withdrawal of diazepam after long-term therapy. Lancet, i, 14021406.Google Scholar
Tyrer, P., Sievewright, N., Ferguson, B., et al (1993) The Nottingham Study of Neurotic Disorder: effect of personality status on response to drug treatment, cognitive therapy and self-help over two years. British Journal of Psychiatry, 162, 219226.Google Scholar
Tyrer, S. P., Walsh, A., Edwards, D. E., et al (1984) Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progress in Neuropsychopharmacology and Biological Psychiatry, 8, 751755.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.